‘Social Licensing’ The Day Two Focal Point of Baffert/NYRA Hearing

The concept of perception versus reality has been a core plank on both sides of the highly publicized “detrimental conduct” case ever since the New York Racing Association (NYRA) first tried to banish trainer Bob Baffert eight months ago. On Tuesday, the second day of a hearing process that could lead to Baffert's exclusion from New York's premier tracks, the murky interpretation of who should be considered the true victim and which entity is in need of protection from harm rose to the forefront in the form of arguments over “social licensing” that at times played out in tense and pointed fashion.

Although Baffert is the most easily identifiable Thoroughbred trainer in North America, the key witness who testified Jan. 25 was not at all a recognizable name within the sport. Some 7 1/2 hours of testimony and cross-examination from four witnesses were anchored by about 90 minutes of debate regarding the opinions and PhD expertise of Dr. Camie Heleski, a University of Kentucky equine sciences professor who specializes in what the general public thinks of as horse racing.

“If somebody carries a lot of weight, if they have a strong visual branding in a certain piece of the industry, that's going to be noticed by a larger group of the public, a larger group of, let's say, horse racing fans than if it was not such a memorable person,” Heleski testified. She later added that, “Anybody that's paying attention to racing is going to know who Bob Baffert is.”

Heleski explained that in general, the public tends to regard any highly publicized news about pharmaceuticals in horse racing as something that could be damaging to the sport's social licensing, which is a way of terming general acceptance.

“Most of the time, they're simply feeling if there was a drug or a medication violation noted, they feel like it's bad. They kind of put it all under the umbrella of doping,” Heleski said.

And when Kelly McNamee, a lawyer representing NYRA, asked her to tie in the public's collective thought process and how it relates to Baffert's history of equine drug positives, his trainee Medina Spirit's betamethasone overage when winning the 2021 GI Kentucky Derby, and the “over 70 horses that have died under the care of Mr. Baffert,” Heleski didn't hesitate to answer that all of those things combined could adversely affect racing's social license to operate.

“I think drug and medication [positives] from a very prominent person carry more weight than people that are not followed as closely…” Heleski said. “[And] if a trainer has a large number of deaths in their stables, that's going to be looked on poorly.”

But under stern cross-examination from Baffert's lead lawyer, W. Craig Robertson III, the University of Kentucky professor at times seemed overwhelmed when challenged to explain how it could be Baffert's fault that the general public doesn't understand the difference between therapeutic medications and doping.

Robertson also hammered home points about Baffert's history of awards for sportsmanship and good deeds within the industry, plus his well-documented contributions to aftercare. He wanted Heleski to explain how, if Baffert is such an allegedly detrimental presence who could hurt NYRA, why didn't any activists protest his presence at Saratoga last summer, and why did the track enjoy record betting handles at that meet despite Baffert trainees being in the entries?

Robertson also attempted to dismantle Heleski's “amorphous” concept of social licensing, which, she admitted, has nothing to do with an actual “license” that a person or entity could apply for based on regulated standards, like a racing license.

But assuming such a concept exists, Robertson asked Heleski if it wasn't also part of NYRA's obligation to treat all trainers fairly as part of that social license to operate.

“They should treat trainers fairly, yes,” Heleski agreed.

And if NYRA singled out one trainer–like Baffert–for allegedly unfair punishment, Robertson wanted her opinion on whether “the public might not like that, either. That could hurt a social license to operate, couldn't it?” Robertson queried.

NYRA's legal team objected to that line of questioning, and hearing officer O. Peter Sherwood wouldn't allow Heleski to answer the question.

Baffert himself was not called upon to speak during the day-long proceedings in New York City. On the Zoom webcast made available by NYRA to the media, the Hall-of-Fame trainer could occasionally be glimpsed sitting alongside his lawyers in a conference room, dressed in a dark sport coat and open-collared white shirt.

Although his facial expressions were hidden behind a mask for pandemic precautions, Baffert's posture suggested tedium more than anxiety. He generally kept his hands folded in front of him, sometimes absently working his thumbs together repetitively while occasionally reaching up to flick his thick, silver-white hair off his forehead. For the most part, he looked more like a gent waiting for a bus than a seven-time Derby-winning trainer waiting to find out if he'd be exiled from one of America's most prominent racing circuits.

In previous legal pleadings that failed to keep Baffert's hearing from happening at all, his attorneys have described these proceedings as a “fait accompli.” Yet despite the fact that NYRA came up with the newly invented process for holding the hearings, the list of charges against Baffert, and was responsible for selecting the hearing officer who will decide Baffert's fate, a federal judge ruled last week that NYRA has a right to move ahead in that manner.

NYRA had outright banished Baffert May 17, 2021, in the wake of Medina Spirit's still-not-adjudicated Derby drug positive, noting that four other Baffert trainees had tested positive for medication overages in roughly the year before that. On July 14, a federal judge granted Baffert a preliminary injunction that allowed him to race at Saratoga, Belmont and Aqueduct. That injunction has since been made permanent, but with the legal stipulation that NYRA must afford Baffert a hearing process before deciding whether to kick him out or not.

NYRA is charging that Baffert's alleged conduct is or has been “detrimental” to three entities: 1) The best interests of racing; 2) The health and safety of horses and jockeys; 3) NYRA business operations.

Dr. Pierre-Louis Toutain, a France-based veterinarian considered an expert in pharmacology and toxicology, testified earlier Tuesday for 1 3/4 hours.

Some of Toutain's testimony tended to drag, in part because he was asked to offer definitions of and uses for phenylbutazone, lidocaine and betamethasone, three of the substances that NYRA purports are related to Baffert's alleged wrongdoing. Toutain also good-naturedly apologized a number of times for English not being his first language as he testified remotely while on a six-hour European time difference.

Toutain provided one of the lighter moments of the day when he politely interrupted a drug question from one of Baffert's attorneys, Clark Brewster, to ask, “Are you a scientist or a lawyer?”

When Brewster replied that he was a lawyer, that cued Toutain to know he shouldn't give too technical an answer,

“Ah, so I have to explain simply–okay!”

General laughter broke some of the inherent tension.

But there was no hint of humor from anyone in the room when a NYRA attorney, Hank Greenberg, asked Toutain if the presence of 21 picograms of betamethasone in Medina Spirit's post-Derby blood would have had the capacity to affect his performance.

“Yes, definitively,” Toutain replied.

But Toutain had been talking strictly about an intra-articular injection of betamethasone, which he said was the prevailing way that drug is administered to horses. So when it was Brewster's turn to cross-examine Toutain, he made sure to ask about betamethasone contained within a topical salve or ointment for a skin rash, which is how Baffert has alleged that the betamethasone found its way into Medina Spirit.

“Topical? I am not sure they use it [that way],” Toutain answered.

Toutain then seemed to be confused about whether Brewster was asking if betamethasone was sometimes administered via patch, like lidocaine (which the attorney was not asking).

Brewster then quickly ended his cross-examination of Toutain.

The post ‘Social Licensing’ The Day Two Focal Point of Baffert/NYRA Hearing appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

‘A Wrecking Ball … To Integrity’: Lawyers For Baffert, NYRA Trade Barbs On Day One Of Exclusion Hearing

There's going to be a lot to unpack in this week's hearing of the New York Racing Association versus trainer Bob Baffert.

In opening statements made by attorneys for the respective sides on Jan. 24, representatives of each made clear that they see a key two-year period in Baffert's career very differently.

Henry M. Greenberg, shareholder in Greenberg Traurig and attorney for NYRA, laid out the organization's frustration with Baffert's recent history of therapeutic drug violations and also his handling of those violations in the national and trade media, highlighting what NYRA sees as a refusal to consistently accept responsibility for those violations.

“What this case is about and what the evidence will show is how one man — this man, the respondent — took a wrecking ball over a one-year period to the integrity of the sport that was so good to him for so many years,” said Greenberg. “He sullied and soiled, in one year, 365 days, three of the great races in America — the Arkansas Derby, the Kentucky Oaks, and the Kentucky Derby. Throughout that period, not once did he take responsibility for his actions, did he express contrition. Time and again, again and again, six times, he would blame others to try to avoid responsibility for his own actions.

“In 2020 and 2021, the only Triple Crown he's responsible for is destroying three Grade 1 races.”

On the first day of the hearing, Greenberg tracked the changes in Baffert's responses to Medina Spirit's post-Kentucky Derby betamethasone overage in the national media — from the trainer denying the horse received the drug at all in a press conference he called after learning of the overage to his insistence days later that the overage was due to the administration of a topical ointment — as well as his representations that other overages, such as Gamine and Charlatan's lidocaine tests in Arkansas and Merneith's dextrorphan test in California, were due to environmental contamination.

“The evidence will show NYRA had an obligation to act,” Greenberg said. “It had an obligation to protect the sport of Thoroughbred racing and its integrity … Racetrack operators like NYRA and Churchill Downs have a social license, you will hear, with the public.”

Attorneys for Baffert say NYRA's objections are overblown and beyond the organization's authority.

“The facts in these case are going to be nothing like what you just heard,” said W. Craig Robertson in his opening statement, following Greenberg's. “Bob Baffert is one of the most respected individuals in racing not just now, but in all time. NYRA, which they've just started, is going to throw at you innuendo, speculation and downright distortions. What I'm going to focus on are facts.”

Robertson pointed out that the drug positives at the heart of NYRA's case — six picked up in a span of 14 months from July 2019 to September 2020 — are for therapeutic substances whose thresholds are measured in small concentrations. Further, he said, racetracks should not be allowed to take regulatory action against a licensee.

“The actions being taken by NYRA are unprecedented,” he said. “You're the only thing standing between NYRA and [this suspension] happening.

“I'm not asking that you treat him any better than any other trainer. I'm just asking that you don't treat him any worse.”

Robertson also chastised NYRA for taking action against Baffert before a ruling has been made in the Kentucky Derby betamethasone case. According to Baffert's attorneys, no hearing has yet taken place in that case before the Kentucky stewards. The Kentucky Horse Racing Commission would not confirm to the Paulick Report last week whether one had been scheduled yet.

Only one witness was called to the stand in the first day of testimony — Rick Goodell, a regulatory attorney who has represented the New York State Gaming Commission in many drug and other rule violations cases over the past 20 years. Part of Goodell's duties in New York were to recommend potential penalties for various rule violations, including drug violations. Greenberg asked Goodell to run through the list of Baffert's drug positives and respective penalties in the context of his experience working for the state of New York. In the case of a lidocaine positives, which comprised two of the six violations at question, Goodell said he would have expected to pursue a 45-day suspension in each case, but offer the trainer 30 for their first lidocaine violation if they agreed not to pursue an appeal. In the case of phenylbutazone, which accounted for two more of the six violations, he expected to pursue 14 but offer a trainer seven days' suspension if they agreed not to appeal.

All told, Goodell said a trainer with Baffert's record in New York would have racked up 240 days' suspension if he did not decline to appeal cases. Baffert did not serve days for any of the six.

(Those six overages were a phenylbutazone from a July 27, 2019 race at Del Mar; a phenylbutazone from an Aug. 3, 2019 race at Del Mar; two overages of 3-hydroxylidocaine at Oaklawn May 2, 2020; one dextrorphan in a July 25, 2020 race at Del Mar, and a betamethasone in the 2020 Kentucky Oaks in September. The Medina Spirit test is not counted towards the six since it hasn't yet been adjudicated.)

Goodell also said that by his reading of the current draft of proposed regulations of the Horseracing Integrity and Safety Authority (HISA), the same record in the same period of time could result in a suspension as long as 18 months.

Of course, as Baffert attorney Clark Brewster pointed out, none of these violations took place in New York under current New York regulations, nor did they take place under HISA regulations, which are still in development. It remains somewhat unclear what could have been called a positive in New York because Goodell said New York keeps a document with drug testing thresholds but that Dr. George Maylin, director of the drug testing lab for New York state, maintains the right to call a positive if he believes a sample indicates a drug was given outside the regulated timeframe, even if it's under the threshold.

Brewster and Robertson also suggested that NYRA's actions here could be motivated by key New York racing personalities who may be “jealous” of Baffert and his success, or tired of losing to him. Goodell maintained he was not qualified to speculate on that.

Goodell's testimony continues on Jan. 25. The hearing is projected to take three to five days total.

The post ‘A Wrecking Ball … To Integrity’: Lawyers For Baffert, NYRA Trade Barbs On Day One Of Exclusion Hearing appeared first on Horse Racing News | Paulick Report.

Source of original post

KHRC Vacates Levamisole Rulings Against Sharp

The Kentucky Horse Racing Commission has vacated the sanctions it imposed on trainer Joe Sharp following five positive tests for levamisole in horses who ran at Churchill Downs in November 2019. A KHRC ruling issued Thursday and first reported by Blood-Horse, read, “Due to the de-classification of levamisole in August 2015 by the Kentucky Horse Racing Commission, all penalties previously assessed to Owner/Trainer Joe Sharp in Stewards' Rulings #21-0006, #21-0008, #21-0010, #21-0011 and #21-0012 are hereby vacated.”

Sharp was suspended 30 days and fined $2,500 by the KHRC last January for the levamisole positives. The trainer also had eight horses test positive for the drug at Fair Grounds and was issued $1,000 fine for each horse, but not suspended for the Louisiana violations. He blamed the levamisole positives on an over-the-counter dewormer he had purchased and used to treat his horses.

While announcing his client was appealing the KHRC decision last January, attorney Clark Brewster told TDN, “The stewards sent out this notice saying [levamisole] is a class B drug. Not only is it not a class B, it's not listed at all. They held a hearing where I strongly urged them to dismiss this and they got real quiet. Then they returned a suspension of 30 days and fines. It was truly astonishing. We expect public servants to apply the law based on what is set forth.”

Brewster said that levamisole is only prohibited when it metabolizes into the drug aminorex, which he said did not happen in the case of Sharp's horses. He also pointed to a 2015 case in which the KHRC suspended trainer Daniel Werre for a full year after a levamisole positive. The suspension was reversed by the Franklin Circuit Court, which cited its finding that the KHRC had improperly classified the drug at the time. Werre was eventually given a seven-day suspension.

The post KHRC Vacates Levamisole Rulings Against Sharp appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Baffert Attorneys Claim Test Proves Ointment Led To Medina Spirit’s Failed Drug Test

Attorneys for the owner and trainer of Medina Spirit, first-place finisher in the 2021 Kentucky Derby, claim tests conducted by a New York laboratory have “definitively confirmed” the horse tested positive for a corticosteroid not through an injection but because of an ointment used to treat a skin rash.

Craig Robertson, attorney for Bob Baffert, and Clark Brewster, representing owner Amr Zedan's Zedan Racing Stables, said tests conducted by Dr. George Maylin, who heads a drug testing laboratory at New York's Morrisville State College, showed the presence of betamethasone valerate, which they claim is found in Otomax ointment. Otomax, manufactured to treat ear infections in dogs, lists betamethasone as one of its ingredients. The test, Robertson and Brewster said, also confirmed the absence of betamethasone acetate, the injectable corticosteroid used to treat inflammation.

“In other words,” Robertson said in a statement, “it has now been scientifically proven that what Bob Baffert said from the beginning was true – Medina Spirit was never injected with betamethasone and the findings following the Kentucky Derby were solely the result of the horse being treated for a skin condition by way of a topical ointment – all at the direction of Medina Spirit's veterinarian.”

The Paulick Report has asked Robertson and Brewster for a full copy of Maylin's report.

Robertson said the test result “should definitively resolve the matter in Kentucky and Medina Spirit should remain the official winner of the 2021 Kentucky Derby.” Brewster had similar sentiments, stating that “Zedan is proud to have stood by Bob and is ecstatic that Medina Spirit will receive the honor of his great victory.”

The Kentucky Horse Racing Commission and board of stewards have yet to conduct a hearing on Medina Spirit's failed drug test, and until a hearing is conducted Medina Spirit will remain the Kentucky Derby winner. In the ewake of the failed drug test, Baffert was ruled off all tracks owned by Churchill Downs Inc. through the conclusion of the 2023 spring-summer meet at the company's flagship track in Louisville, Ky. Churchill Downs also said horses trained by Baffert are not eligible for qualifying points for the Kentucky Derby.

A spokesperson for the commission could not be reached for comment on Maylin's testing, which attorneys for Baffert and Zedan sought through a court order.

The rules of Kentucky racing do not appear to differentiate between administration of betamethasone or other drugs through injection or other means. In section 1 in the regulations relating to medication, testing procedures and prohibited practices, the definition for “administer” states: “to apply to or cause the introduction of a substance into the body of a horse.”

The full statements from Robertson and Brewster follow:

Craig Robertson: The testing of the split urine sample of MEDINA SPIRIT has now been completed by Dr. George Maylin, Director of the New York Drug Testing & Research Program.  By Order of the Franklin Circuit Court in Kentucky, this urine was tested “to determine if the alleged topical administration of OTOMAX could have resulted in the finding of betamethasone” in MEDINA SPIRIT following the 2021 Kentucky Derby.  Those results have now definitively confirmed that the betamethasone present in MEDINA SPIRIT's system did indeed come from the topical ointment OTOMAX and not an injection.  In other words, it has now been scientifically proven that what Bob Baffert said from the beginning was true – MEDINA SPIRIT was never injected with betamethasone and the findings following the Kentucky Derby were solely the result of the horse being treated for a skin condition by way of a topical ointment – all at the direction of MEDINA SPIRIT's veterinarian.

The betamethasone in an injection is betamethasone acetate.  The betamethasone in the topical ointment is betamethasone valerate.  Only betamethasone acetate is addressed and regulated in the rules of racing in Kentucky.  Thus, the presence of betamethasone valerate in MEDINA SPIRIT, which resulted from a topical ointment, is not a rules violation.  Dr. Maylin's testing not only confirmed the presence of betamethasone valerate, but also the absence of betamethasone acetate.  This should definitively resolve the matter in Kentucky and MEDINA SPIRIT should remain the official winner of the 2021 Kentucky Derby.

Since May, Mr. Baffert has been the subject of an unfair rush to judgment.  We asked all along that everyone wait until the facts and science came to light.  Now that it has been scientifically proven that Mr. Baffert was truthful, did not break any rules of racing, and MEDINA SPIRIT's victory was due solely to the heart and ability of the horse and nothing else, it is time for all members of racing to come together for the good of the sport.  Mr. Baffert has been a tremendous ambassador for the sport throughout his 46 year Hall of Fame career and he has every intention of continuing to do so.

Clark Brewster: As Legal counsel for, and on behalf of, Abr Zedan and Zedan Racing Stable, owner of Medina Spirit, winner of the 147th Kentucky Derby, it is extremely gratifying to learn that the New York Racing Laboratory through its Director Dr George Marlin has scientifically confirmed that no Betamethazone Acetate was found in the post race urine specimen of Medina Spirit. Dr Maylin reported that components of an ointment used to treat a skin lesion was confirmed through metabolite confirmation and that no Acetate that is part of the injectable Betamethazone was present. The Kentucky Racing Commission has steadfastly enacted rules relating to corticosteroid joint injection and have drawn a bright line rule that no injections are permitted within 14 days of a race. Now there is zero doubt that the 14 day rule some thought might have been violated by the earlier less specific testing is revealed as premature judgment. That groundless accusation is without scientific merit.
Zedan is proud to have stood by Bob and is ecstatic that Medina Spirit will receive the honor of his great victory.

The post Baffert Attorneys Claim Test Proves Ointment Led To Medina Spirit’s Failed Drug Test appeared first on Horse Racing News | Paulick Report.

Source of original post

Verified by MonsterInsights